Testing JAK-3 Kinase inhibitor in cerebral Malaria animal model
Dr. Gros studied cerebral malaria (CM). CM is the most severe neurological complication of a Plasmodium falciparum infection, resulting in seizures, coma, and death. CM is characterized by severe inflammation in the brain, and it is this inflammation that makes the disease invariably lethal. Anti-inflammatory compounds may help to prevent this inflammation-associated brain damage. Janus kinase 3 (JAK-3) is a key enzyme in an important inflammation-signaling pathway, and thus inhibiting JAK-3 could inhibit cerebral inflammation. BVGH connected Dr. Gros with Pfizer, which shared a JAK-3 inhibitor with suitable characteristics for testing in Dr. Gros’ CM animal model.